Health Affairs, 23, no. 1 (2004): 10-22 doi: 10.1377/hlthaff.23.1.10 © 2004 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Cockburn, I. M. Search for Related Content PubMed PubMed Citation Articles by Cockburn, I. M. Related Collections Pharmaceuticals Research And Technology

Industry Priorities

The Changing Structure Of The Pharmaceutical Industry

Rising research and development (R&D) expenditures by pharmaceutical companies are, in part, a consequence of changing industry structure, particularly the rise of the biotechnology sector. The creation of a market for biomedical science and increased vertical competition within the industry are likely to spur innovation and raise productivity, but they also could induce socially wasteful spending and weaken academic science. With innovation increasingly dependent on financially vulnerable firms and complex contractual arrangements, R&D investment might be becoming more sensitive to price controls or other cost containment measures.

                      What's this?

This article has been cited by other articles:

				J. H. Barton and E. J. Emanuel The Patents-Based Pharmaceutical Development Process: Rationale, Problems, and Potential Reforms JAMA, October 26, 2005; 294(16): 2075 - 2082. [Abstract] [Full Text] [PDF]